Last reviewed · How we verify
Ad5FGF-4
Ad5FGF-4 is a gene therapy that delivers fibroblast growth factor 4 (FGF-4) via an adenovirus vector to promote angiogenesis and improve blood flow in ischemic tissues.
Ad5FGF-4 is a gene therapy that delivers fibroblast growth factor 4 (FGF-4) via an adenovirus vector to promote angiogenesis and improve blood flow in ischemic tissues. Used for Severe coronary artery disease with refractory angina, Critical limb ischemia / peripheral arterial disease.
At a glance
| Generic name | Ad5FGF-4 |
|---|---|
| Also known as | Generx, alferminogene tadenovec |
| Sponsor | Angionetics Inc. |
| Drug class | Gene therapy / Angiogenic agent |
| Target | Fibroblast Growth Factor 4 (FGF-4) |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The drug uses a replication-deficient adenovirus serotype 5 (Ad5) as a vector to deliver the FGF-4 gene directly into ischemic myocardium or other tissues. FGF-4 is a potent angiogenic factor that stimulates the formation of new blood vessels, thereby improving perfusion and oxygen delivery to damaged or ischemic tissue. This approach aims to restore functional blood flow in patients with severe coronary artery disease or peripheral arterial disease who are not candidates for conventional revascularization.
Approved indications
- Severe coronary artery disease with refractory angina
- Critical limb ischemia / peripheral arterial disease
Common side effects
- Chest pain or angina
- Myocarditis or pericarditis
- Fever
- Injection site reactions
Key clinical trials
- Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia (PHASE3)
- Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease (PHASE3)
- Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization (PHASE3)
- Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3) (PHASE2, PHASE3)
- Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad5FGF-4 CI brief — competitive landscape report
- Ad5FGF-4 updates RSS · CI watch RSS
- Angionetics Inc. portfolio CI